Yarrow Bioscience registers Phase 2 trial of YB-101 in Graves' Disease
A newly listed study will test YB-101 against placebo for safety, tolerability, and thyroid function effects in patients with Graves' Disease.
Yarrow Bioscience's week centered on the registration of a new Phase 2 study for its Graves' Disease candidate.
- YB-101, an injectable drug given subcutaneously, is being studied in a Phase 2, randomized, placebo-controlled trial sponsored by Yarrow Bioscience, Inc. for Graves' Disease, listed as recruiting. This study is being conducted to look at the effect YB-101 has on thyroid function, with participants receiving YB-101 or Placebo subcutaneously in a Phase 2 trial for Graves' Disease.1 The trial plans to enroll 232 participants (estimated)1 and lists primary completion for December 2027 (estimated)1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.